To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

NCT ID: NCT04671303

Last Updated: 2025-05-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-01
• Study Completion Date: 2023-07-27

Brief Summary

This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate in First-line Treatment of Advanced no-squamous and No-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.

Detailed Description

This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate in First-line Treatment of Advanced No-squamous and No-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.

This study is a single arm, phase II study, including 18 to 36 subjects; Common Terminology Criteria for Adverse Events 5.0 standard was used to evaluate adverse events of drugs, and Response Evaluation Criteria In Solid Tumors 1.1 was used to evaluated efficacy.

Conditions

Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.

Take medicine continuously for 3 weeks (21 days) for 1 cycle.

Group Type: EXPERIMENTAL

Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

Intervention Type: DRUG

Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.

Take medicine continuously for 3 weeks (21 days) for 1 cycle.

Interventions

Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.

Take medicine continuously for 3 weeks (21 days) for 1 cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Locally advanced and/or metastatic NSCLC diagnosed histologically and/or cytologically;

2. Age 18 and above; Eastern Cooperative Oncology Group Physical condition: 0~1; The expected survival time is more than 3 months;

3. The previous report confirmed the presence of an EGFR gene exon 19 deletion mutation or exon 21 L858R mutation, and the investigator verified that the report reflects the patient's current genetic status.

4. There is at least one measurable lesion other than brain lesion defined by Response Evaluation Criteria In Solid Tumors 1.1 standard;

5. The main organs are functioning well,Adequate laboratory indicators.

6. Women of childbearing age should agree to use contraceptives during the study period and for a period of six months after the study; Negative serum or urine pregnancy test within 7 days prior to study inclusion, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study period;

7. Patients voluntarily participated in this study, signed informed consent, and had good compliance.

Exclusion Criteria

1. Prior history of targeted Epidermal Growth Factor Receptor therapy and anti-angiogenic drugs

2. Received chemical or biological drugs after the diagnosis of advanced stage;

3. Subjects had undergone surgery , radiation therapy or other anticancer therapies within 4 weeks prior to the commencement of study treatment; Subjects who have previously received local radiation therapy may be enrolled if the following conditions are met: more than 4 weeks after the end of radiation therapy ;

4. Within 2 weeks before the start of the study, patients were treated with Chinese medicines

5. Imaging shows that the tumor has invaded the periphery of important blood vessels or the investigator has determined that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the follow-up study.

6. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage ;

7. Brain metastases with symptoms or symptom control time less than 2 weeks;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Yuankai Shi

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yuankai SHI, Doctor

Role: PRINCIPAL_INVESTIGATOR

Chinese Academy of Medical Sciences and Peking Union Medical College

Locations

cancer hospital Chinese academy of medical sciences

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

ALTN-AFTN-II-01

Identifier Type: -

Identifier Source: org_study_id